Table 1.
Patient characteristics and outcome before and after initiating fluvoxamine as an add-on to the standard-of-care (SOC), early outpatient care for symptomatic COVID-19.
| Fluvoxamine + SOC (N = 53) |
SOC (N = 50) |
p | |
|---|---|---|---|
| Median Age (years) | 45 (IQR 41–55) | 49 (IQR 39–60) | 0.65 |
| Male Gender n (%) | 25 (47) | 29 (58) | 0.33 |
| BMI (kg/m2) | |||
| Median | 26.4 (24.0–31.3) | 25.8 (23.6–28.3) | 0.25 |
| Comorbidities n (%) | |||
| Obesity (BMI > 30) | 15 (28) | 7 (14) | 0.10 |
| Hypertension | 10(19) | 7 (14) | 0.60 |
| Diabetes | 5(9) | 6(12) | 0.76 |
| Dyslipidemia | 6(11) | 3(6) | 0.49 |
| Autoimmunity | 5(9) | 3(6) | 0.72 |
| Neurologic | 3(9) | 2(4) | 1 |
| Thrombophilia | 3(6) | 0 | 0.24 |
| Cancer | 3(6) | 0 | 0.24 |
| COPD | 1(2) | 1(2) | 1 |
| Other | 28(53) | 22(44) | 0.43 |
| Vaccination n (%) | |||
| Fully vaccinated | 38 (72) | 40 (80) | 0.37 |
| Booster shot | 16 (30) | 10 (20) | 0.26 |
| Treatment n (%) | |||
| Enoxaparin prophylaxis | 15 (28) | 11 (22) | 0.50 |
| Budesonide | 53 (100) | 50 (100) | 1 |
| Outcome n (%) | |||
| Clinical deterioration | 2 (4%) | 8 (16%) | 0.048 |
| Hospitalization/ICU | 1/0 | 6/1 | 0.05 |
| Deaths | 0 (0) | 0 (0) | - |
BMI: Body Mass Index; ICU: Intensive Care Unit; IQR: Interquartile Range.